Sphingosine 1-phosphate (S1P) regulates diverse biological processes, including mitosis, by binding to the S1P family of G-protein coupled receptors. The aim of the study was to determine the pattern of S1P receptor expression and to investigate the effects of S1P on intracellular calcium levels and proliferation in the rat thyroid cell line PC Cl(3). S1P(2) and S1P(3) mRNA and proteins were detected in PC Cl(3) cells, as well as in FRTL-5 rat thyroid cells. In addition, S1P(5) mRNA was present at low levels, but not S1P(1) or S1P(4). In PC Cl(3) cells, S1P invoked calcium release from intracellular stores, but not calcium entry. The Ca(2+) release was mediated by phospholipase C and inositol 1,4,5-trisphosphate. S1P attenuated the TSH-evoked cAMP increase in a pertussis toxin-sensitive manner. S1P per se did not affect the proliferation of the cells, but attenuated the proliferation evoked by a combination of insulin and TSH. Furthermore, S1P attenuated the PMA-evoked proliferation. S1P(2) expression was positively regulated by insulin and PMA. S1P itself transiently upregulated S1P(2) receptor mRNA, while TSH had a net downregulating effect on S1P(2) expression. In summary, S1P modulates central intracellular signaling cascades and is antiproliferative in PC Cl(3) cells. S1P(2) receptor expression is modulated by insulin and TSH, two central growth factors in thyroid cell regulation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mce.2004.12.001DOI Listing

Publication Analysis

Top Keywords

s1p2 receptor
12
receptor expression
12
rat thyroid
12
cl3 cells
12
s1p
10
sphingosine 1-phosphate
8
proliferation s1p2
8
thyroid cells
8
thyroid cell
8
s1p attenuated
8

Similar Publications

Objective: Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). S1P receptor expression on cardiac cells is involved in cardiac conduction. We report cardiovascular treatment-emergent adverse events (TEAEs) associated with S1P receptor modulators and other cardiovascular events in the etrasimod UC clinical programme.

View Article and Find Full Text PDF

Blocking the Sphingosine-1-Phosphate Receptor 2 (S1P) Reduces the Severity of Collagen-Induced Arthritis in DBA-1J Mice.

Int J Mol Sci

December 2024

Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02446, Republic of Korea.

The amount of sphingosine 1-phosphate (S1P) found in the synovial tissue of individuals with rheumatoid arthritis is five times greater than that in those with osteoarthritis. Our study aims to determine whether inhibiting S1P can mitigate collagen-induced rheumatoid arthritis (CIA) by using an S1P antagonist, JTE-013, alongside DBA-1J wild-type (WT) and knock-out (KO) mice. CIA causes increases in arthritis scores, foot swelling, synovial hyperplasia, pannus formation, proteoglycan depletion, cartilage damage, and bone erosion, but these effects are markedly reduced when JTE-013 is administered to WT mice.

View Article and Find Full Text PDF

Background: The aim of our study was to determine the role of sphingolipids, which control proliferation and apoptosis, in the placenta of pregnant women with pregnancy-associated breast cancer (PABC) after chemotherapy compared with healthy patients.

Methods: We analyzed (by the PCR method) the gene expression of key sphingolipid metabolism enzymes (sphingomyelinases (SMPD1 and SMPD3), acid ceramidase (ASAH1), ceramide synthases (CERS 1-6), sphingosine kinase1 (SPHK1), sphingosine-1-phosphate lyase 1 (SGPL1), and sphingosine-1-phosphate receptors (S1PR1, S1PR2, and S1PR3)) and the content of subspecies of ceramides, sphingosine, and sphingosine-1-phosphate in seven patients with PABC after chemotherapy and eight healthy pregnant women as a control group.

Results: We found a significant increase in the expression of genes of acid ceramidase (ASAH1), sphingosine-1-phosphate lyase 1 (SGPL1), sphingosine kinase (SPHK1), and ceramide synthases (CERS 1-3, 5, 6) in the samples of patients with PABC during their treatment with cytostatic chemotherapy.

View Article and Find Full Text PDF

Targeting the tumor immune microenvironment: GPCRs as key regulators in triple-negative breast cancer.

Int Immunopharmacol

December 2024

Department of Biochemistry and Molecular Biology, Jining Medical University, Jining, China. Electronic address:

Triple-negative breast cancer (TNBC) poses a significant clinical challenge due to its aggressive nature and limited therapeutic options. Recent research underscores the pivotal role of G protein-coupled receptors (GPCRs) in shaping the tumor immune microenvironment (TIME) within TNBC. This review focuses on four principal GPCRs-chemokine receptors, sphingosine-1-phosphate receptors, prostaglandin E2 receptors, and lactate receptors-that have garnered substantial attention in TNBC studies.

View Article and Find Full Text PDF

Whole blood concentrations of fingolimod and its pharmacologically active metabolite fingolimod phosphate obtained during routine health care of patients with multiple sclerosis.

Mult Scler Relat Disord

December 2024

Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Czech Republic.

Background: Fingolimod is a first-in-class, orally administered drug indicated for the treatment of relapsing-remitting multiple sclerosis. It acts as an immunomodulator, is classified as a "disease-modifying therapy", and its main mechanism of action is the modulation of sphingosine-1-phosphate receptors. In this prospective pilot study, whole blood concentrations of fingolimod and fingolimod phosphate obtained during routine health care were measured.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!